Company Overview of HealthLinx Limited
As of March 12, 2015, HealthLinx Limited was acquired by Manalto Limited, in a reverse merger transaction. HealthLinx Limited engages in the identification and development of novel, non-invasive, serum, and plasma based multi marker diagnostics. It primarily develops Ovplex, an ovarian cancer diagnostic; and IgY. The company is based in Melbourne, Australia.
50 Queen Street
Melbourne, VIC 3000
Key Executives for HealthLinx Limited
HealthLinx Limited does not have any Key Executives recorded.
HealthLinx Limited Key Developments
HealthLinx Limited, Special/Extraordinary Shareholders Meeting, Feb 23, 2015
Feb 16 15
HealthLinx Limited, Special/Extraordinary Shareholders Meeting, Feb 23, 2015.
HealthLinx Limited, Annual General Meeting, Jan 12, 2015
Nov 21 14
HealthLinx Limited, Annual General Meeting, Jan 12, 2015., at 11:00 AUS Eastern Standard Time. Location: The offices of Quinert Rodda & Associates Pty Ltd, Suite 1. Agenda: To consider the Annual Financial Statements of the Company for the financial year ended 30 June 2014 together with the declaration of the Directors, the Directors' Report, the Remuneration Report and the Auditor's Report; to consider the adoption of remuneration report; to consider the election of director Mr. Timothy Chapman; to consider the re-election of director Mr. Michael Quinert; to consider the approval for disposal of main undertaking; to consider the approval of placement facility; and to consider the ratification of prior issue.
Healthlinx Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014
Nov 19 14
HealthLinx Limited reported audited consolidated earnings results for the year ended June 30, 2014. For the period, the company reported revenue of AUD 7,192 against AUD 34,721 for the same period last year. Total revenue and other income was AUD 64,734 against AUD 50,493 for the same period last year. Loss before income tax was AUD 363,677 against AUD 4,365,297 for the same period last year. Net loss was AUD 270,682 or 0.0219 cents per basic and diluted share against AUD 3,952,613 or 0.006 cents per basic and diluted share for the same period last year. Net cash used in operating activities was AUD 353,525 against AUD 661,153 for the same period last year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|